# Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

> **NCT05898373** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College** · enrollment: 120 (estimated)

## Conditions studied

- Salivary Gland Cancer

## Interventions

- **DRUG:** vedicitumomab (Edisil, RC48）
- **DRUG:** vedicitumomab in combination with pyrrolizidine
- **DRUG:** RC48 in combination with a platinum-based chemotherapeutic agent
- **DRUG:** RC48 in combination with teraplizumab

## Key facts

- **NCT ID:** NCT05898373
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06-07
- **Primary completion:** 2025-06-06
- **Final completion:** 2026-06-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898373, "Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05898373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*